drugset
Drugs / Galinpepimut-S
last change Dec 2025 re-read 2 minutes ago

Galinpepimut-S

also known as polyvalent WT1 peptide vaccine · WT-1 analog peptide vaccine

Vaccine targets WT1

Developed for
acute myeloid leukemia · malignant pleural mesothelioma · myelodysplastic syndrome · acute lymphoblastic leukemia · colorectal cancer · leukemia · lung cancer · malignant mesothelioma
+5 more · ovarian cancer · plasma cell myeloma · primary peritoneal carcinoma · small cell lung carcinoma · triple-negative breast carcinoma
Investigated by
Sellas Life Sciences Group · Memorial Sloan Kettering Cancer Center · Innovive Pharmaceuticals · LumaBridge · Merck Sharp & Dohme LLC · National Cancer Institute (NCI)
+2 more · PPD Development, LP · United States Department of Defense

Trials 8 · a red edge is where a trial was stopped

today NCT04229979 · Ph 3 NCT03761914 · Ph 1/2 NCT04040231 · Ph 1 NCT01827137 · Ph 1/2 NCT01266083 · Ph 2 NCT01265433 · Ph 2 NCT00398138 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04040231 Jul 2019 → Nov 2024 Wilms tumor, malignant pleural mesothelioma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 1 NCT00398138 Oct 2006 → Jun 2009 leukemia, lung cancer, malignant mesothelioma, myelodysplastic syndrome +1 Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT03761914 Sep 2019 → Jul 2022 acute myeloid leukemia, colorectal cancer, ovarian cancer, small cell lung carcinoma +1 Sellas Life Sciences Group Completed No outcome recorded
Phase 1/2 NCT01827137 Apr 2013 → Dec 2016 plasma cell myeloma Sellas Life Sciences Group Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01266083 Jan 2011 → Sep 2016 acute lymphoblastic leukemia, acute myeloid leukemia Sellas Life Sciences Group Completed No outcome recorded
Phase 2 NCT01265433 Dec 2010 → Nov 2016 malignant pleural mesothelioma Sellas Life Sciences Group Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04229979 Feb 2021 → Dec 2025 overdue acute myeloid leukemia Sellas Life Sciences Group Active not recruiting No outcome recorded
Phase not stated1 trial
— NCT05593185 — acute myeloid leukemia, myelodysplastic syndrome Sellas Life Sciences Group Available No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as galinpepimut-S “Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.” NCT04040231 ↗
7

NCT04229979 ↗

NCT04040231 ↗

NCT01266083 ↗

NCT03761914 ↗

NCT01827137 ↗

NCT01265433 ↗

NCT05593185 ↗
Known as polyvalent WT1 peptide vaccine “These preliminary data suggest that this polyvalent WT1 peptide vaccine can be administered safely to patients with a resulting immune response.” PMID 20400682 ↗ Apr 2010
Known as WT-1 analog peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00398138 ↗
Action Deplete “train the immune system to recognize and kill the cancerous cells containing WT1” NCT01827137 ↗
Modality Vaccine “polyvalent Wilms tumor gene 1 (WT1) peptide vaccine” PMID 20400682 ↗ Apr 2010
Route Subcutaneous “Vaccinations will be administered subcutaneously” NCT00398138 ↗
Target WT1 “polyvalent Wilms tumor gene 1 (WT1) peptide vaccine” PMID 20400682 ↗ Apr 2010